Aims: The aims of this study were to evaluate the effects of sodium tanshinone IIA sulfonate (STS) on left ventricular (LV) remodelling after for ST-elevated myocardial infarction (STEMI).
| INTRODUC TI ON
Along with the advance of the intensive care system and revascularization therapy in particular primary percutaneous coronary intervention (PCI), the prognosis for ST-elevation myocardial infarction (STEMI) has dramatically improved. As the number of survivors has increased, a concomitant increase in pathologic cardiac remodelling patients after MI has become a huge problem. Cardiac remodelling characterized by progressive changes in ventricle volume and impaired global function was associated with poor clinical outcome. 1 Moreover, once remodelling is established with clinical heart failure symptoms, therapies to reverse remodelling and/or improve symptoms have limited effects. Thus, the development of novel and potentially more effective devices or pharmaceutical agents would be to prevent the remodelling from occurring in the early stage of MI setting is urgently needed.
It has been already reported that degradation of extracellular matrix (ECM), occurring after heart infarction, associates with a consequent loss of myocardium tissue integrity that allows the infarct zone to be stretched by intraventricular pressure, thereby inducing the adverse left ventricular (LV) remodelling. Compelling evidence indicates polymorphonuclear neutrophils (PMN) infiltrated in coronary plaques and the infarcted myocardium plays a pivotal role in the pathologic infarct extension and the stunning of potentially viable myocardium. 2 In addition to producing inflammatory chemokines, neutrophils have been demonstrated mediated tissue damage by releasing matrix-degrading enzymes and reactive oxygen species. 3 A number of clinical trials reported the increased ratio of circulating neutrophils to lymphocyte could be recognized as a prognostic factor to predict both major adverse cardiac events and chronic LV remodelling in patients suffered from MI. 4, 5 Moreover, abnormal elevations in neutrophil count in blood of patients with acute coronary syndrome undergoing primary percutaneous coronary intervention (PCI) associates with larger infarct sizes and worsening of cardiac systolic and diastolic function. 6 Importantly, promising results obtained from preclinical models studying several pharmacological approaches aimed at interfering with the myocardial neutrophil's recruitment, confirmed their beneficial effects on reducing infarct size and the extent of the ultimate cardiac injury. 7 Hence, suggesting that neutrophils depletion strategies could be a desirable pharmacological strategy in patients with MI at a higher risk of LV remodelling. 
| ME THODS

| Study design
The study is a randomized, parallel-group, controlled study comparing STS with saline control in patients who survived a STEMI after successful reperfusion. Ethics committees at Guangdong Provincial
Hospital of CM reviewed and gave their approval (B2011-41-01). All principles of the Declaration of Helsinki were applied. This trial was registered in clinicaltrials.gov (NCT02524964).
| Participates and intervention
The eligible patients were aged 18-80 years, who presented within 
| Effectiveness endpoints
The primary effectiveness endpoint is the %∆ LVEDVi measured by echocardiography from baseline to 6 months after PCI. Secondary effectiveness endpoints include composite of all-cause death, recurrence of MI documented by symptoms and with a new rise in cardiac biomarkers and hospitalization due to heart failure events adjudicated by an independent clinical events committee using standardized definitions. Additional exploratory proteomics analyses were also performed in hope for better mechanistic explanation of the observed clinical effects of STS treatment.
| Echocardiographic measurement of cardiac remodelling
Resting transthoracic echocardiograms will be performed before randomization and then at 6-month follow-up visit. Two-dimensional echocardiographic studies were recorded and submitted to the independent, blinded laboratory for a centralized assessment of quantitative analysis after quality control. As previous reports, the selected images were digitized to obtain endocardial contours and LV cavity volumes at end diastole and end systole from apical orthogonal views including 4-and 2-chamber. 12 The modified Simpson rule was used to calculate EF value using the standard formula according to American Society of Echocardiography guideline recommendations. All measurements were measured by an experienced sonographer from 5 cardiac cycles and the mean values were considered for analysis.
| Proteomics analysis of peripheral blood samples
The blood samples from both STS (n = 9) and saline control (n = 9) groups after 5-day treatment were prepared and assessed the Gene ontology (GO) analysis in the set of differentially expressed factors was performed with DAVID Bioinformatics Resources 6.8 databases to investigate the associated biological process, cellular component and molecular function. 13 Functional categories were enriched and the top 10 GO functional categories were selected.
Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used for pathway analysis to discover a relation that was not easily visible from the changes of individual proteins.
| Quantification of the neutrophils-derived granule components in peripheral blood
To further confirm the proteins response to STS treatment, plasma and serum from patients received either STS (n = 48) or saline (n = 48) before and after 5-day treatment were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) procedure following manufacturer's protocols (R&D systems Minneapolis, MN, USA).
| Sample size
The sample size determination is based on the primary endpoint, estimated change in LVEDVi from baseline to 6 months after STS treatment. To have >80% power and detect a treatment difference of 5% in change of LVEDVi between STS and saline control (with allocation ratio of 1:1) using a two-sided significance level of 0.05, a minimum of 46 patients were required in each arm. A therapeutic decrease in LVEDV of 5 mL/m 2 has been shown to be associated with favourable effects on mortality.
14 Additional patients will be recruited to account for potential dropouts.
| Statistical analysis
All pharmacokinetic parameters were summarized as mean ± standard deviation, median (first quartile, third quartile), percent coefficient of variation as appropriate. General linear mixed models were used to perform an intention-to-treat analysis that consists of all randomized patients for the effectiveness analyses. The primary and secondary endpoints were assessed using analysis of covariance with major determinants, including demographic parameters 
| RE SULTS
| Patients and baseline clinical characteristics
Between February 2014 and December 2016, 101 patients were randomized (50 to STS and 51 to saline control). Figure 1 illustrates study enrolment and randomization. There was one patient in the STS group and two in the control group lost to follow-up.
Baseline demographics stratified by treatment arm are shown in Figure 1 ). Among these patients, there were no significant differences in LVEDVi, LVESVi or LVEF between the two groups at baseline. The LV function was well preserved, with a mean ± SD ejection fraction of 52.73%±7.92%. No differences occurred in the baseline characteristics between the two groups (Table 1) .
Overall, all patients displayed thrombolysis in myocardial infarction (TIMI) 3 flow within the infarct-related artery, and there was high adherence to all post-MI guideline-recommended therapies.
In the overall cohort, 65.35% of patients were treated with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, in comparison with 73.27% of those who received β-adrenergic blocking agents.
| Echocardiographic endpoints
The echocardiographic measurements at 6-month follow-up are shown in Figure 2 Left ventricular end-systolic volume index (LVESVi) slightly increased in the control group while was reduced in the STS group (1.82 ± 1.52 and −2.36 ± 1.33 mL/m 2 , respectively, P < 0.01).
Consequently, a statistically significant difference occurred in LVEF between the two groups at the 6-month follow-up: a significantly higher LVEF (55.81 ± 6.98 and 49.94 ± 7.19%, respectively, P < 0.01) were found in the STS group compared with the control group.
| Clinical outcome
Overall, 6-month mortality was 2.97% (3 of 101 patients), one patient (2.04%) in the STS group and two patients (4%) in the control group.
Two patients died of heart failure during the first month after index MI (one in the STS group and one in the control group), and one patient died of ischaemic stroke at 4 months after MI in the control group.
Eight (16.0%) patients in the control group and three (6.12%) in the STS group had a non-fatal recurrent MI documented by angiography and received revascularisation. One patient (2.04%) in the STS group and two patients (4.0%) in the control group had ventricular arrhythmia;
3 of 49 patients in the STS group (6.12%) and 7 of 50 patients in the control group (14.0%) had hospital readmission for congestive heart failure. Collectively, combined analysis of the most important adverse cardiovascular events (including death, reinfarction, hospitalization for heart failure and malignant arrhythmia [4 (8.16%) and 13 (26.00%) in the STS and control groups respectively]) showed an absolute reduction (P = 0.019). Moreover, no side effects secondary to STS treatment were observed suggesting the compound is well tolerated.
| Effects of STS treatment on levels of biomarkers detected by proteomics
As proteomic analysis has been already documented as a powerful tool for the identification of novel mechanisms in response to diverse pharmacologic therapies, we further investigate the mechanism un- As shown in Figure 3C , applied KEGG analysis allowed us to identify particular pathways that were significantly affected by differentially expressed interleukins and their interactions with cytokine-cytokine cellular receptors that eventually affected the cellular chemotaxis, proliferation and re-organization of the extracellular matrix. These data encouraged the further quantitative assessment of biologically active factors that can be released from neutrophils and potentially affect myocardium.
| Quantification of the neutrophil granulesderived enzymes
As previous studies already documented that neutrophils play an essential role in tissue remodelling after several tissue injures and after MI, we now measured effects of STS treatment on blood levels of neutrophils-derived granule components, including neutrophil elastase, myeloperoxidase, proteinase 3, neutrophil gelatinase-associated lipocalin (NGAL), MMP-8 and MMP-9, in both groups of patients following MI. 15 Peripheral blood obtained from patients just at the enrolment and after 5-day treatment with either STS or saline were measured using ELISA with indicated antibodies. Results shown there were no differences in these neutrophils-derived granule components between two groups at the enrolement. Interestingly, after STS treatment, the absolute count of neutrophils was not changed compared to that in the control group. However, a statistically significant difference occurred in neutrophils-derived granule components between the two groups after 5-day treatment: the mean values of F I G U R E 3 Proteomics and biosystematics analysis. A, Cluster analysis of the differentially expressed cytokines in the plasma compared between the STS patients and the control patients. B, Significant functional annotations of differentially expressed cytokines using GO analysis according to biological process ranked by enrichment score. C, KEGG pathways analysis of the differentially expressed proteins 
| D ISCUSS I ON
This study demonstrates that STS treatment of MI patients who underwent the successful surgical revascularization significantly attenuates their LV remodelling and decreases in LVEDVi of ≥5% that associate with a concomitant reduction of the adverse clinical outcome. Furthermore, the degree of reduction in adverse events correlated with the magnitude of the LVEDVi decrease lending credence to a cause-effect relationship.
The current results are consistent with the previous reports that
LVEDVi is correlated with beneficial clinical outcome, and a shortterm favourable therapy effect on LVEDVi or LVEDV is associated with the improvement of longer term mortality. 16 It has been also demonstrated that the extent of pathologic LV remodelling correlated with the risk of adverse cardiovascular events such that each 10-mL increase in LVEDV corresponded to an adjusted hazard ratio has been shown that the selective pharmacologic inhibition of neutrophil elastase protects against myocardial stunning after ischaemia/ reperfusion in swine and reduce the infarct size. [19] [20] [21] [22] On the other hand, it has been demonstrated that proteinase 3 exacerbate heart failure through cleaving angiotensinogen into angiotensin, activating proinflammatory factors and degrading extracellular matrix including fibronectin and collagen IV. 23, 24 In addition, proteinase 3 levels in the plasma serve as a prognostic risk marker for death or rehospitalization for heart failure in post-MI patients. 24 Similarly, high plasma NGAL levels before PCI has been shown to independently predict all-cause mortality for patients with MI, the underlying mechanisms involves protecting MMP-9 from degradation. 25, 26 The evidence of higher total and active MMP-8 levels were shown in patients with F I G U R E 4 Quantification of neutrophils-derived granule components. Levels of neutrophils-derived granule components, including neutrophil elastase, myeloperoxidase, proteinase 3, NGAL, MMP-8 and MMP-9 in patients receiving STS or saline control were assessed by ELISA. NGAL, neutrophil gelatinase-associated lipocalin. MMP, matrix metalloproteinases LV rupture than those without rupture, indicating this neutrophil collagenase may promote infarct rupture in humans. 27 Further studies suggested MMP-8 degrades collagens via cleaving type I α1 and α2 chains and subsequently promotes neutrophils migration, and neutrophils depletion inhibits early collagen degradation as a consequence of the lack MMP-8. 28, 29 Infiltrating neutrophils are an early source of MMP-9 after MI both with and without reperfusion in humans and multiple animal models. 30 
| CON CLUS IONS
In conclusion, our study demonstrated that addition of STS to current practice guidelines-recommended therapies further reduces the progressive LV remodelling and improves the clinical outcome after acute MI. As, STS treatment did not reduce a total number of neutrophils detected in peripheral blood, but decreased levels of circulating chemokines and proteases, that could be released from their granules and vesicles, we suggest that the immediate daily IV treatment of MI patients with STS mitigates the early release of numerous factors that would be otherwise attracted by the degradation products of the injured myocardial matrix and ultimately exacerbate remodelling of the post-MI heart. Therefore, at this point we might speculate that this phytomedicine might stabilize integrity of cellular membranes, thereby reducing the net level of neutrophil's exocytosis and rupture of their granules and vesicles.
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